Unknown

Dataset Information

0

Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.


ABSTRACT:

Purpose

Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, heterogeneous disease with few therapeutic strategies that significantly prolong survival. Innovative therapies for mCRPC are needed; however, the development of new therapies relies on accurate imaging to assess metastasis and monitor response. Standard imaging modalities for prostate cancer require improvement and there remains a need for selective and sensitive imaging probes that can be widely used in patients with mCRPC.

Experimental design

We evaluated the transmembrane protease fibroblast activation protein alpha (FAP) as a targetable cell surface antigen for mCRPC. Genomic and IHC analyses were performed to investigate FAP expression in prostate cancer. Our FAP-targeted antibody imaging probe, [89Zr]Zr-B12 IgG, was evaluated by PET/CT imaging in preclinical prostate cancer models.

Results

Analysis of patient data documented FAP overexpression in metastatic disease across tumor subtypes. PET imaging with [89Zr]Zr-B12 IgG demonstrated high tumor uptake and long-term retention of the probe in the preclinical models examined. FAP-positive stroma tumor uptake of [89Zr]Zr-B12 IgG was 5-fold higher than the isotype control with mean %ID/cc of 34.13 ± 1.99 versus 6.12 ± 2.03 (n = 3/group; P = 0.0006) at 72 hours. Ex vivo biodistribution corroborated these results documenting rapid blood clearance by 24 hours and high tumor uptake of [89Zr]Zr-B12 IgG by 72 hours.

Conclusions

Our study reveals FAP as a target for imaging the tumor microenvironment of prostate cancer. Validation of [89Zr]Zr-B12 IgG as a selective imaging probe for FAP-expressing tumors presents a new approach for noninvasive PET/CT imaging of mCRPC.

SUBMITTER: Hintz HM 

PROVIDER: S-EPMC7683011 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.

Hintz Hallie M HM   Gallant Joseph P JP   Vander Griend Donald J DJ   Coleman Ilsa M IM   Nelson Peter S PS   LeBeau Aaron M AM  

Clinical cancer research : an official journal of the American Association for Cancer Research 20200707 18


<h4>Purpose</h4>Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, heterogeneous disease with few therapeutic strategies that significantly prolong survival. Innovative therapies for mCRPC are needed; however, the development of new therapies relies on accurate imaging to assess metastasis and monitor response. Standard imaging modalities for prostate cancer require improvement and there remains a need for selective and sensitive imaging probes that can be widely used in patien  ...[more]

Similar Datasets

| S-EPMC5411699 | biostudies-literature
| S-EPMC7464128 | biostudies-literature
| S-EPMC7922638 | biostudies-literature
| S-EPMC4926532 | biostudies-literature
| S-EPMC8750680 | biostudies-literature
| S-EPMC5962344 | biostudies-literature
2015-02-09 | E-MTAB-3175 | biostudies-arrayexpress
| S-EPMC6249271 | biostudies-literature
| S-EPMC9323375 | biostudies-literature
2011-11-01 | GSE21217 | GEO